ArticleBMC infectious diseases2025
It never rains but pours: disseminated nocardiosis in a renal transplant patient from Nigeria - a case report.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNocardiosis is a rare opportunistic infection with high mortality and a tendency to relapse. The causative Nocardia spp. are filamentous Gram-positive aerobic bacteria. The lungs and brain are commonly affected and bacteraemia is rare, occurring in < 8% of cases. Solid organ transplant recipients receiving steroid immunosuppression are particularly at risk. The mainstay of treatment is prolonged antibiotic combination therapy, typically including trimethoprim-sulfamethoxazole. CASE PRESENTATION: We present the case of a renal transplant recipient from Nigeria with disseminated Nocardia cyriacigeorgica infection with lung and brain abscesses and, unusually, bacteraemia. Most recommended antibiotic regimens were precluded by severe deterioration of graft function and anaemia whilst being unable to receive blood products due to religious beliefs. He was initially treated with intravenous ceftriaxone 2g twice a day and meropenem 1g twice a day before commencing continuation therapy with oral minocycline 100mg twice a day. Despite resolution of the acute cavitating complications of Nocardia infection with antibiotic therapy and controlled reduction of immunosuppression, graft function continued to deteriorate. Serum BK viral load was found to be very high at 6.40 × 107 copies/mL, prompting a graft biopsy which showed BK virus nephropathy with severe inflammation. The patient later recalled he had received pulsed methylprednisolone prior to travel for presumptive rejection.
conclusionsTo the best of our knowledge, this is the first time concomitant BK virus nephropathy and Nocardia cyriacigeorgica bacteraemia have been described in the literature. The presence of bloodstream infection amenable to culture significantly aided in the diagnosis of nocardiosis and therefore in the prompt initiation of treatment. In our patient’s case, intravenous meropenem and ceftriaxone then oral minocycline were effective in the treatment of disseminated Nocardia cyriacigeorgica with lung and cerebral abscesses. The rarity of bloodstream nocardiosis alongside florid BK virus nephropathy demonstrated clear overimmunosuppression and the importance of a ‘for cause’ graft biopsy before immunosuppression escalation. Whilst rare, the significant associated mortality makes nocardiosis an important differential to consider in transplant recipients with unexplained fever. Furthermore, as access to transplantation increases globally, access to quality post-transplant care must too. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.